A detailed history of Invesco Ltd. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Invesco Ltd. holds 16,324 shares of AUTL stock, worth $58,276. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,324
Previous 11,071 47.45%
Holding current value
$58,276
Previous $70,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$3.33 - $5.68 $17,492 - $29,837
5,253 Added 47.45%
16,324 $56,000
Q1 2024

May 14, 2024

BUY
$5.39 - $7.29 $5,352 - $7,238
993 Added 9.85%
11,071 $70,000
Q4 2023

Feb 12, 2024

SELL
$2.13 - $6.63 $502 - $1,564
-236 Reduced 2.29%
10,078 $64,000
Q3 2023

Nov 13, 2023

SELL
$2.32 - $3.36 $893 - $1,293
-385 Reduced 3.6%
10,314 $24,000
Q2 2023

Aug 11, 2023

BUY
$1.64 - $3.21 $17,546 - $34,343
10,699 New
10,699 $25,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $325M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.